BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28759518)

  • 1. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
    Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
    Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
    Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
    Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
    Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
    J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
    Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
    Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
    Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
    Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
    Huang SY; Bolch WE; Lee C; Van Brocklin HF; Pampaloni MH; Hawkins RA; Sznewajs A; DuBois SG; Matthay KK; Seo Y
    Mol Imaging Biol; 2015 Apr; 17(2):284-94. PubMed ID: 25145966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
    Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
    Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for
    Seo Y; Huh Y; Huang SY; Hernandez-Pampaloni JM; Hawkins RA; Gustafson WC; Vo KT; Matthay KK
    Med Phys; 2019 May; 46(5):2477-2486. PubMed ID: 30761545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
    Bolster AA; Hilditch TE; Wheldon TE; Gaze MN; Barrett A
    Br J Radiol; 1995 May; 68(809):481-90. PubMed ID: 7788233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
    George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
    Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma
    Chimeno JM; Sebastià N; Torres-Espallardo I; Balaguer J; Candela-Juan C; Loaiza JL; Adria M; Ibanez-Rosello B; Cañete A; Martí-Bonmatí L; Montoro A
    Int J Radiat Biol; 2019 Mar; 95(3):314-320. PubMed ID: 30496023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
    Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
    J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma.
    Sudbrock F; Schmidt M; Simon T; Eschner W; Berthold F; Schicha H
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1279-90. PubMed ID: 20179922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
    Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
    Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
    Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
    J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
    Flower MA; Fielding SL
    Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.